- Conditions
- Dercum's Disease Lipomas
- Interventions
- RZL-012, Vehicle
- Drug
- Lead sponsor
- Raziel Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 1,163
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Osteoarthritis of Hip, Regional Anesthesia, Other Acute Postoperative Pain, Total Hip Arthroplasty, Peripheral Nerve Block, Lumbar Plexus Nerve Block, Parasacaral (Sciatic) Nerve Block
- Interventions
- Continuous Lumbar Plexus Block, Parasacral Nerve Block, Ropivacine 0.2%, Bupivacaine 0.0625%
- Procedure · Drug
- Lead sponsor
- Rita Merman
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Heart Failure, Systolic, Inflammation
- Interventions
- Anakinra, Placebo
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Metabolism and Nutrition Disorder, Obesity
- Interventions
- liraglutide, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 846 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 67
- States / cities
- Vestavia Hills, Alabama • Peoria, Arizona • Jonesboro, Arkansas + 57 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- LY2127399, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 24 more
- Conditions
- Gonadotropin Deficiency
- Interventions
- Testosterone 1% Gel, Acyline, Dutasteride, Ketoconazole, HCG, placebo dutasteride, placebo ketoconazole
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 55 Years · Male only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Atopic Dermatitis
- Interventions
- Placebo, Tralokinumab Dose 1, Tralokinumab Dose 2, Tralokinumab Dose 3
- Other · Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Rogers, Arkansas • Fremont, California + 19 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Medi-546, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • Phoenix, Arizona + 27 more
- Conditions
- Dermatitis
- Interventions
- Placebo, Risankizumab
- Biological
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 35 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Efpeglenatide SAR439977, Placebo, Background therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 18 more
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- AGA2118, Placebo
- Drug · Other
- Lead sponsor
- Angitia Biopharmaceuticals
- Industry
- Eligibility
- 55 Years to 80 Years · Female only
- Enrollment
- 379 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Gainesville, Georgia • Albuquerque, New Mexico + 2 more
- Conditions
- Multiple Sclerosis (MS)
- Interventions
- Fingolimod, Ofatumumab, Siponimod, Fingolimod placebo, Siponimod placebo, Ofatumumab placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 3 more
- Conditions
- Atopic Dermatitis
- Interventions
- Lutikizumab, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 19
- States / cities
- Fountain Hills, Arizona • Los Angeles, California • Sacramento, California + 16 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Tocilizumab 162 mg, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 656 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 44
- States / cities
- Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 36 more
- Conditions
- Crohn's Disease
- Interventions
- Placebo for Risankizumab SC, Risankizumab IV, Placebo for Risankizumab IV, Risankizumab SC, Risankizumab On-Body Injector (OBI)
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 1,336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 111
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 91 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Upadacitinib, Adalimumab, Upadacitinib Matching Placebo, Adalimumab Matching Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 487 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 85
- States / cities
- Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more
- Conditions
- Spinal Cord Injuries, Chronic Spinal Cord Injury, Subacute Spinal Cord Injury
- Interventions
- NVG-291, Placebo Injection
- Drug
- Lead sponsor
- NervGen Pharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Psoriasis
- Interventions
- Placebo for Risankizumab, Risankizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 34
- States / cities
- Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 30 more
- Conditions
- Type 1 Diabetes
- Interventions
- Neulasta (Pegylated), Placebo, Mixed Meal Tolerance Test (MMTT), Blood test, DNA Test
- Drug · Dietary Supplement · Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 12 Years to 45 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Glatiramer Acetate, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 25
- States / cities
- Cullman, Alabama • Fresno, California • La Jolla, California + 17 more
- Conditions
- Hypertension
- Interventions
- Tonlamarsen, Placebo
- Drug
- Lead sponsor
- Kardigan, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 39
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 36 more
- Conditions
- Atopic Dermatitis
- Interventions
- Tralokinumab, Placebo
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 802 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 37 more
- Conditions
- Nasal Polyps, Chronic Rhinosinusitis
- Interventions
- Omalizumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 249 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 22 more
- Conditions
- HIV Infections, Lipodystrophy
- Interventions
- Placebo, Serostim® 4 mg, Serostim® 2 mg
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 22 more